you year thank us results to everyone for full join taking ShockWave's the afternoon the to Good XXXX. and review and Debbie. Thanks for quarter time fourth
III another delivered demonstrated new in including randomized a reimbursement year shipping trial, team of U.S., and regulatory in in important U.S., XXX we in broke approved new in outstanding the the in had ShockWave launched quarter approvals manufacturing follow-up just several countries, products accomplishments our coronary Costa one-year highlight XXXX, achievements. new key in superiority added over strong across had Japan and facility an Rica. XX on the the a few and two in ground wins PAD many globe, Our China, accounts with To
of from which revenue than revenue for quarterly fourth the from doubling revenues fourth record a achieved We the quarter $XXX $XXX the XX% than more million, increase This XXXX. brought XXXX, of our million XXXX. to quarter in more our year was of
results about What we growth the geographies. was and all and these encouraging found contribution lines across most product
quarter versus our fourth remarkable revenue fourth and XX% peripheral up revenue over was for over over international up U.S. XXXX XX% was the across for Our coronary, up for rather U.S. business, XX% quarter board. XXXX
then share here I'd updates business, to with start provide will Isaac like results. our the additional the insights few call, the some recent in But from ShockWave. Dan financial side Later and of on a details activity around commercial some will at
much been continues regulatory product sooner coronary We trend mid-December, our of for approvals. team our than are in have CX+ as approval we pleased their FDA expected to efficient granted was which
the the European The high this in CX+ half adds from gives launch a U.S. second the limited to in we plan of of to confidence us As launch XX the going year. performance experience pulses reminder, CX+, more in XX% in XXX. and
the new product IVL a we utility to expectation experience, expand plan that of launch extension, coronary that products improve in with first the by series penetration. the and coronary further each increase is customer This new will
We're year. January lower IVL largest this year, been markets, X has in Germany IVL than because for number yet of the for coronary in increased on appreciably IPL large procedures. obviously $XXX,XXX at coronary penetration gap has pleased all Germany European European of was the of per nations of approximately funding that reimbursement PCIs in other largely
We believe in reimbursement the increases principal will meaningfully IVL the reduce to Germany. in utilization barrier
to expansion. team German of are support We market double our presently on anticipated order to working size in the
in the receiving been our catheter, U.S. LX limited great We've currently in peripheral which feedback on is launch
given Isaac color going later may has in catheter remember, dense a vessels. call. in purpose-built was well great launch address this you calcium very provide been insights. the will to resistant As limited has us and large more The bit
and We well-attended Veeva hosted multiple both fourth [Vet]. at quarter, the including events during
as We female study also be both week, our these the showcase III IVL IVL. observational IVL, six as design. updates sharing data forward conferences. next calcium, well of sessions study look EMPOWER We shared on our on discussions CRT for PAD where further great nodular are highlighting It presentation from another to more at should there including at
believe Angiography coronary facilities great As of treatment SCAI, on-site January, of of as surgical a the restricted and IVL you Cardiovascular seen, in published a or status. with backup Previous endorsement IVL. is guidelines option recommended the all regardless in treatment safety updated this surgical backup. including may cath late guidelines, Interventions labs, of Society We U.S. have to ASCs, which included
Our are started, reimbursement in more a just effectively. color thus provide have far. while Japan very we earnest launch will can in encouraged in now that appropriate later in confidence launch with the And in CX we generally bit is Isaac CX getting we launch commenced call. place, the January
has agreement community enthusiasm the post for acquire we announced definitive we Reducer than grown the Systems Lastly, largely a we January, Neovasc entered earlier because potential to and responded into positively of had announcement, more that our anticipated. even in clinical
technologies angina. is close their acquisition the has address patients to option in this the of to leverage patient step refractory The of not steady for product underserved quarter Neovasc, very treatment to a solid ShockWave's population by debilitating develop of a a to which mission commercialize do of who unique strategic elegantly a large populations. the novel This and talents potential world-class currently team our cadence is of end have for set
turn I Isaac, to call anticipate month that we from top XXXX. revenue million to for in last will full $XXX of I XXXX, call we to as in reiterate, delivering the million XX% line shared our year of Before range $XXX XX% the representing growth the
and details With then broader over financial business will turn share Isaac? more to the results. on that, Isaac I'll Dan the and call